• Applications & Products
    • Applications
    • Products
  • Media Formulation
  • About InVitria
  • News & Blog
  • Contact Us
  • Terms
  • Privacy
  • Sitemap
Performance. Defined.
  • 1-800-916-8311 or Email Us
  • iconMy Account
  • iconView Cart
  • Applications & Products
    • Applications
      • Gene Therapy
      • Cell Therapy
      • T-Cell Immunotherapy
      • Vaccine Production
      • Antibody Production
      • Final Formulation
    • Product Types
      • Blood-Free Cell Culture Media
      • Cell Culture Components
      • Synthetic Serum Replacements
      • Recombinant Albumin
      • Recombinant Transferrin
      • Recombinant Human Lysozyme
      • Recombinant Human Interleukins
    • Products
      • Cellastim S® – Recombinant human albumin
      • Exbumin® – Recombinant human albumin excipient
      • Optibumin® 20 – Recombinant human albumin
      • Optibumin® 25 – Recombinant human albumin
      • Optiferrin® – Recombinant human transferrin
      • Lacromin® – Recombinant human holo lactoferrin
      • ITS AF – Blood-free cell culture media supplement
      • ITSE + A – Blood-free cell culture media supplement
      • ITSE Animal-Free® – Blood-free cell culture media supplement
      • Lysobac® – Recombinant human lysozyme
      • OptiLeukin 2 – Recombinant human IL-2
      • OptiKine™ LIF – Leukemia Inhibitory Factor
      • OptiVERO® – Chemically-defined complete VERO media
  • About InVitria
  • News & Blog
  • Contact Us
  • Knowledge Base
  • Applications
  • Products
  • Contact Us
  • Home
  • Evonik Interview: How Recombinant Albumin De-Risks Cell Therapy Manufacturing

Evonik Interview: How Recombinant Albumin De-Risks Cell Therapy Manufacturing

Published on 19 July 2026

InVitria + Evonik Partnership Spotlight: Recombinant HSA for Reliable Cell & Gene Therapy Scale-Up

Author: Evonik, Featured Experts: Jake Hanks, Director of Business Development, InVitria & Sabrina Metze, Evonik

Source: Evonik News, July 2026

InVitria and Evonik logos displayed side by side on a white background, separated by a thin vertical gray line. The InVitria logo includes the tagline "Performance. Defined." beneath the company name, while the Evonik logo includes the tagline "Leading Beyond Chemistry.

Introduction Our partner Evonik has published a detailed interview featuring InVitria’s Director of Business Development, Jake Hanks. The discussion focuses on how recombinant human serum albumin helps biopharma manufacturers reduce risks in cell therapy production through greater consistency, purity, and supply security.

Full Interview Link Read the complete Evonik interview

Partnership Overview Evonik distributes InVitria’s recombinant human albumin portfolio globally under the CreaCyte® brand. This includes:

  • Cellastim® S – Lyohpilized powder for cell culture media & upstream use
  • Exbumin® – Lyophilized powder Excipient-grade for formulation stability
  • Optibumin® 20 & Optibumin® 25 – Ready-to-use excipient grade liquid solutions for biomanufacturing, 20 & 25% w/v

Key Benefits Highlighted

  • Chemically defined, animal-origin-free alternative to plasma-derived HSA
  • Superior lot-to-lot consistency and purity
  • Closed-system compatible packaging (Optibumin® 25 in sterile 100 mL bags)
  • Enhanced supply chain security for commercial-scale programs
  • Strong regulatory alignment (cGMP, ISO 9001, FDA/EMA familiarity)

Key Quotes

“Evonik is distributing our recombinant human albumin portfolio globally under the CreaCyte® brand… Combined with Evonik’s global reach, this allows us to support customers from early development through to commercialization.” — Jake Hanks, Director of Business Development, InVitria

“Optibumin® 25 is the first recombinant human serum albumin available as a 25% liquid solution… a true replacement in both format and concentration.” — Jake Hanks, InVitria

As cell and gene therapies scale, reliable raw materials become critical. Recombinant albumin eliminates variability and contamination risks associated with blood-derived sources while enabling seamless integration into GMP closed-system workflows.

Ready to explore recombinant albumin for your process?

View Recombinant Albumin here: https://invitria.com/type/recombinant-human-albumin/

Footnotes

  1. Evonik Interview – Link
  2. InVitria CreaCyte® / Optibumin® product data
Start New Search

Quick Search Links

Application:

Antibody Production

Cell Therapy

Final Formulation

Gene Therapy

T-Cell Immunotherapy

Vaccine Production

Product Category:

Cell Culture Supplements

Albumin

Cell Culture Media

Interleukins

Lactoferrin

LIF

Lysozyme

Single Components

Transferrin

Product:

Exbumin® – Recombinant human albumin excipient

ITS Animal-Free™ – Blood-free cell culture media supplement

ITSE Animal-Free® – Blood-free cell culture media supplement

ITSE+A™ – Blood-free cell culture media supplement

Lacromin® – Recombinant human holo-lactoferrin

OptiLeukin™ 2 – Recombinant human interleukin-2

OptiVERO®

Cellastim® S – Recombinant human albumin

Optibumin® 20 – Recombinant human albumin

Optibumin® 25 – Recombinant human albumin

Optiferrin® – Recombinant human transferrin

OptiKine™ LIF – Leukemia Inhibitory Factor

Lysobac® – Recombinant human lysozyme

Document Type:

Application Notes

Blog

Case Studies

Catalog

Data Sheets

Infographics

Interviews

Journal Articles (DOI Links)

News

Posters

Product Brochures

Product Specifications

Regulatory Documents

SDS

Use Guidelines

Webinar

White Papers

Cell Line:

B Lymphocyte

CHO

ESC

HEK293

Hematopoetic Stem Cells

Hybridoma

iPSC

Mesenchymal Stem Cells

Natural Killer Cells

Neural Stem Cells

T Lymphocyte

VERO

  • 2718 Industrial Drive • Junction City, KS 66441
  • 800-916-8311
  • © 2026 InVitria

    • Terms
    • Privacy
    • Sitemap